Liver transplant specialist Marie Sinclair reported on August 24 that a seventh Victorian patient suffered severe liver injury after injecting a counterfeit product labeled as retatrutide, an experimental weight-loss peptide still in clinical trials and unapproved by any regulator worldwide. The patient deteriorated after a second dose. Sinclair and the Therapeutic Goods Administration now suspect a single contaminated batch is circulating in Victoria, though no laboratory result has confirmed that theory. ABC News reported the seventh case as an escalation of a cluster first flagged in June.
Professor Robyn Langham, the TGA's chief medical advisor, told the ABC that "the localised nature" of the hospitalizations pointed toward "a batch problem" confined to Victoria. She stressed that her assessment was not the product of a formal investigation. Sinclair, who has treated multiple patients in the cluster, commissioned chemical testing of the counterfeit vials but offered no timeline for results. "We don't have any testing results to support that. It's purely a hypothesis at this stage," she said.
Retatrutide is owned and developed by US pharmaceutical company Eli Lilly, which is running clinical trials for obesity and diabetes management. No vial sold outside those trials carries regulatory approval from the TGA, the US Food and Drug Administration, or any other national agency. Langham made the distinction explicit: "The retatrutide that's being sold is not the retatrutide that's currently in clinical trials." Every product marketed under the name is counterfeit by definition.
Figure 1: The suspected counterfeit retatrutide distribution pathway and the Victoria-based cluster of liver injury cases under review.
How Counterfeit Vials Reach Consumers
Victoria's Chief Health Officer Dr. Caroline McElnay issued the original alert on June 19 after six cases of acute liver toxicity surfaced since January. The Sydney Morning Herald reported that the products had been "purchased online, through friends and through social media accounts." Health officials believe versions of the product are sold under labels including Retatrutide, Reta, R-10, and R-20, marketed online for fat loss, muscle growth, recovery, and anti-aging. The seventh case, arriving two months after the initial alert, indicates those distribution channels remain active.
The marketing language surrounding these products borrows from clinical-sounding terminology while operating entirely outside clinical oversight. Langham told the ABC the TGA is "particularly worried about young people using unapproved peptides being promoted on social media," adding: "What concerns us most is that adolescents, young children are buying these and injecting them into themselves." Eating-disorder dietitian Alex Rodrigues separately identified unregulated peptides being sold or shared in gym communities as a growing concern in Australia, per ABC News reporting on the trend. The pathway from a creator's post to a consumer's injection happens without a prescription, a pharmacist, or a manufacturing standard.
McElnay's June alert warned that "unapproved peptide products, particularly those that are injected, carry significant safety risks, including contamination, infection or local tissue damage." Gastroenterologist Darcy Holt, who treated one of the earlier Victorian patients, warned that severe liver injury can progress to organ failure requiring transplant.
Pending Tests and an Unidentified Toxin
Sinclair described a consistent clinical pattern: liver injuries appeared "within a few weeks" of injection. The seventh patient's deterioration after only a second dose fits that trajectory. The ABC contacted all other state and territory health departments to determine whether the cluster extended beyond Victoria. Canberra Health Services confirmed it had detected liver damage from products sold as retatrutide but declined to specify case numbers, citing low figures. No other jurisdiction reported a comparable cluster.
The batch hypothesis remains unproven because the specific contaminant has not been identified. Sinclair's commissioned tests are in progress. Langham noted that hospital admissions linked to unapproved peptides are occurring across Australia, not only in Victoria, and stated: "The risks are real, they are not theoretical." Yet she also cautioned that the grey-market peptide supply chain produces products with no verified manufacturing, no clinical-trial safety data, and no quality-control documentation.
Under Australian law, selling, supplying, or advertising unapproved peptides like retatrutide is illegal. The TGA has warned social-media influencers that "large fines and penalties apply to illegal advertising" of unapproved peptides, including retatrutide and GLP-1 medications. Whether those warnings have altered the volume of product moving through direct messages, gym networks, and coded online listings is unclear from available records. The question of how peptide legality varies across jurisdictions is addressed in this Peptides Agora guide.
Sinclair expects the caseload to grow. "This is something I think we are going to continue to see with peptides if the unregulated market continues," she told the ABC. Her laboratory tests on the counterfeit vials have not returned a result identifying a specific toxin, and until they do, the chemical cause of seven liver injuries remains undetermined.
